Karl-Erik Andersson to Treatment Outcome
This is a "connection" page, showing publications Karl-Erik Andersson has written about Treatment Outcome.
Connection Strength
0.546
-
Williams JK, Dean A, Lankford S, Criswell T, Badlani G, Andersson KE. Determinates of muscle precursor cell therapy efficacy in a nonhuman primate model of intrinsic urinary sphincter deficiency. Stem Cell Res Ther. 2017 01 06; 8(1):1.
Score: 0.073
-
Andersson KE. Treatment of lower urinary tract symptoms: agents for intraprostatic injection. Scand J Urol. 2013 Apr; 47(2):83-90.
Score: 0.055
-
Andersson KE. Drugs for lower urinary tract symptoms--anything new? J Urol. 2012 Aug; 188(2):349-50.
Score: 0.053
-
Andersson KE, de Groat WC, McVary KT, Lue TF, Maggi M, Roehrborn CG, Wyndaele JJ, Melby T, Viktrup L. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn. 2011 Mar; 30(3):292-301.
Score: 0.048
-
Gratzke C, Streng T, Stief CG, Alroy I, Limberg BJ, Downs TR, Rosenbaum JS, Hedlund P, Andersson KE. Cannabinor, a selective cannabinoid-2 receptor agonist, improves bladder emptying in rats with partial urethral obstruction. J Urol. 2011 Feb; 185(2):731-6.
Score: 0.048
-
Füllhase C, Soler R, Gratzke C, Brodsky M, Christ GJ, Andersson KE. Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction. BJU Int. 2010 Jul; 106(2):287-93.
Score: 0.044
-
Abdel-Hamid IA, Jannini EA, Andersson KE. Premature ejaculation: focus on therapeutic targets. Expert Opin Ther Targets. 2009 Feb; 13(2):175-93.
Score: 0.042
-
Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004 Jan; 3(1):46-53.
Score: 0.029
-
Andersson KE. Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists. World J Urol. 2002 Apr; 19(6):390-6.
Score: 0.026
-
Chapple C, Andersson KE. Tamsulosin: an overview. World J Urol. 2002 Apr; 19(6):397-404.
Score: 0.026
-
Andersson KE, Chapple CR, Höfner K. Future drugs for the treatment of benign prostatic hyperplasia. World J Urol. 2002 Apr; 19(6):436-42.
Score: 0.026
-
De Nunzio C, Roehrborn CG, Andersson KE, McVary KT. Erectile Dysfunction and Lower Urinary Tract Symptoms. Eur Urol Focus. 2017 10; 3(4-5):352-363.
Score: 0.019
-
Soler R, Andersson KE, Chancellor MB, Chapple CR, de Groat WC, Drake MJ, Gratzke C, Lee R, Cruz F. Future direction in pharmacotherapy for non-neurogenic male lower urinary tract symptoms. Eur Urol. 2013 Oct; 64(4):610-21.
Score: 0.014
-
Jin LH, Andersson KE, Han JU, Kwon YH, Park CS, Shin HY, Yoon SM, Lee T. Persistent detrusor overactivity in rats after relief of partial urethral obstruction. . 2011 Oct; 301(4):R896-904.
Score: 0.012
-
Mangera A, Andersson KE, Apostolidis A, Chapple C, Dasgupta P, Giannantoni A, Gravas S, Madersbacher S. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol. 2011 Oct; 60(4):784-95.
Score: 0.012
-
Christ G, Andersson KE, Atala A. The future of bladder research: molecular profiling, new drug targets, gene therapy, and tissue engineering. Curr Urol Rep. 2007 Mar; 8(2):95-9.
Score: 0.009
-
Uckert S, Hedlund P, Andersson KE, Truss MC, Jonas U, Stief CG. Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future. Eur Urol. 2006 Dec; 50(6):1194-207; discussion 1207.
Score: 0.009